Found: 16
Select item for more details and to access through your institution.
Improved Treatment Engagement Among Patients with Diabetes Treated with Insulin Glargine 300 U/mL Who Participated in the COACH Support Program.
- Published in:
- Diabetes Therapy, 2018, v. 9, n. 5, p. 2143, doi. 10.1007/s13300-018-0501-6
- By:
- Publication type:
- Article
An exploratory analysis of the cost‐effectiveness of insulin glargine 300 units/mL versus insulin glargine 100 units/mL over a lifetime horizon using the BRAVO diabetes model.
- Published in:
- Diabetic Medicine, 2024, v. 41, n. 5, p. 1, doi. 10.1111/dme.15303
- By:
- Publication type:
- Article
Cost‐effectiveness analysis of once‐daily insulin glargine 300 U/mL versus insulin degludec 100 U/mL using the BRAVO diabetes model.
- Published in:
- Diabetic Medicine, 2023, v. 40, n. 9, p. 1, doi. 10.1111/dme.15112
- By:
- Publication type:
- Article
Real‐world outcomes of addition of insulin glargine 300 U/mL (Gla‐300) to glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy in people with type 2 diabetes: The DELIVER‐G study.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 8, p. 1617, doi. 10.1111/dom.14739
- By:
- Publication type:
- Article
A pragmatic randomized clinical trial of insulin glargine 300 U/ mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 11, p. 2004, doi. 10.1111/dom.14152
- By:
- Publication type:
- Article
Cover Image, Volume 22, Issue 11.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 11, p. 1, doi. 10.1111/dom.14229
- By:
- Publication type:
- Article
Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real-life clinical trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 11, p. 1995, doi. 10.1111/dom.14116
- By:
- Publication type:
- Article
Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 8, p. 1906, doi. 10.1111/dom.13751
- By:
- Publication type:
- Article
Much Ado About Nothing? A Real-World Study of Patients with Type 2 Diabetes Switching Basal Insulin Analogs.
- Published in:
- Advances in Therapy, 2014, v. 31, n. 5, p. 539, doi. 10.1007/s12325-014-0120-1
- By:
- Publication type:
- Article
Post Hoc Analysis Evaluating the Impact of Antihyperglycemic Background Therapies on Attainment of A1C Targets Without Hypoglycemia in the ACHIEVE Control Pragmatic, Real-Life Study.
- Published in:
- Diabetes Spectrum, 2021, v. 34, n. 4, p. 407, doi. 10.2337/ds20-0079
- By:
- Publication type:
- Article
105-LB: Real-World Outcomes of Addition of Insulin Glargine 300 U/mL (Gla-300) to GLP-1RA Therapy in People with Type 2 Diabetes (PWD2): The DELIVER-G Study.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-105-LB
- By:
- Publication type:
- Article
103-LB: Real-World Persistence, Adherence, Health Care Resource Utilization, and Costs in People with Type 2 Diabetes (T2D) Switching from Basal Insulin (BI) to Second-Generation BI (Insulin Glargine 300 U/mL [Gla-300]) vs. First-Generation BI (Insulin Glargine 1
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-103-LB
- By:
- Publication type:
- Article
1038-P: Insulin Glargine 300 U/ml (Gla-300) vs. First-Generation Standard-of-Care Basal Insulin Analogs (SOC-BI) in Insulin-Naïve Patients with Type 2 Diabetes (T2D): Impact of Renal Function on the Outcomes of the Randomized Pragmatic Real-Life Achieve Control S
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1038-P
- By:
- Publication type:
- Article
1087-P: A Randomized Pragmatic Real-World Clinical Trial Comparing Insulin Glargine 300 U/mL (Gla-300) with Standard of Care First-Generation Basal Insulins (SoC-BIs) in Insulin-Naïve Patients with Type 2 Diabetes: Twelve-Month Analysis of the ACHIEVE Control Study
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1087-P
- By:
- Publication type:
- Article
Expression of Voltage-Gated Calcium Channels in Tumor Cell Lines of Neuroectodermal or Other Origin.
- Published in:
- Annals of the New York Academy of Sciences, 1988, v. 540, n. 1, p. 389, doi. 10.1111/j.1749-6632.1988.tb27110.x
- By:
- Publication type:
- Article
Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)
- Published in:
- Clinical Diabetes, 2023, v. 41, n. 3, p. 425, doi. 10.2337/cd22-0096
- By:
- Publication type:
- Article